Drugs / MG56 Mannosylated
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02654223 | Dec 2015 → Nov 2021 | rhinitis | Inmunotek S.L. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG56 Mannosylated | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02654223 ↗ |
| Route | Subcutaneous | “administered via either the subcutaneous or sublingual route” PMID 38989287 ↗ Jun 2024 |